3 news items
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
MNKD
29 May 24
to increase capacity for formulation and early asset development in upgraded Boston area R&D spaceNon-cash deal includes royalty
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
MNKD
PULM
29 May 24
of our Bedford, Mass., R&D facility along with all leasehold improvements
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
MNKD
8 May 24
resulted in efficiencies which contributed to a lower effective cost per unit. Research and development ("R&D") expenses
- Prev
- 1
- Next